Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.77 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.72 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.72 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.72 |
| ▸ | AKT1 | P31749 | 1/20 | 0.72 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.71 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phytic Acid SCHEMBL9325946 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL9164308 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL1682030 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL17006482 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8467566 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL1681701 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL9741350 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL15374707 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytate SCHEMBL136587 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL12138455 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516359-B | Medicine for LCT poisoning | UNIV MAINZ JOHANNES GUTENBERG | 2013-08-28 | — | — | CN | claimed |
| EP-2432797-A2 | PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | Verenium Corporation (US) | 2012-03-28 | — | — | EP | claimed |
| US-20120066781-A1 | PHYTASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-15 | — | — | US | claimed |
| CN-106866726-B | A kind of method of Solid phase extraction separation phytic acid in crude extract from phytic acid | 华中农业大学 | 2018-06-01 | — | — | CN | disclosed |
| CN-106866726-A | A kind of method of Solid phase extraction separation phytic acid in crude extract from phytic acid | 华中农业大学 | 2017-06-20 | — | — | CN | disclosed |
| CN-103242362-B | Membrane technique prepares the production method of High-purity Phytic Acid calcium | HEFEI UNIVERSITY OF TECHNOLOGY (CN) | 2015-08-26 | — | — | CN | disclosed |
| EP-2617823-B1 | Phytases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140363502-A1 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration | RESVERATROL PARTNERS LLC (US) | 2014-12-11 | — | — | US | disclosed |
| CN-103242362-A | Production method for preparing high-purity calcium phytate by utilizing membrane technology | UNIV HEFEI TECHNOLOGY | 2013-08-14 | — | — | CN | disclosed |
| EP-2584897-A1 | RESVERATROL-CONTAINING COMPOSITIONS AND METHODS OF USE | Resveratrol Partners, Llc (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-102958362-A | Compositions containing resveratrol and methods of use | RESVERATROL PARTNERS LLC | 2013-03-06 | — | — | CN | disclosed |
| US-20040018599-A1 | Enhanced production from almond hulls of products such as inositol and inositol phosphates | RABINOWITZ ISRAEL N (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1084257-B1 | A STRAIN E.COLI JM83/pKP2 TRANSFORMED WITH A NOVEL PLASMID AND PHYTASE PRODUCED THEREFROM | KOREA INST SCI & TECH (KR) | 2003-11-12 | — | — | EP | disclosed |
| US-6277623-B1 | VECTOR FOR USE AS TOOL IN GENETIC ENGINEERING | DAESUNG MICROBIOLOGICAL LABS. CO., LTD. (KR) | 2001-08-21 | — | — | US | disclosed |
| EP-1084257-A1 | A STRAIN E.COLI JM83/pKP2 TRANSFORMED WITH A NOVEL PLASMID AND PHYTASE PRODUCED THEREFROM | Korea Institute of Science and Technology (KR) | 2001-03-21 | — | — | EP | disclosed |
| WO-1998044125-A1 | A STRAIN E.COLI JM83/pKP2 TRANSFORMED WITH A NOVEL PLASMID AND PHYTASE PRODUCED THEREFROM | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1998-10-08 | — | — | WO | disclosed |
| WO-1993019759-A1 | VITAMIN D DERIVATIVE FEED COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0302772-B1 | CALCITONIN COMPOSITION FOR NASAL ADMINISTRATION | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-09-30 | — | — | EP | disclosed |
| US-4072670-A | Low phytate isoelectric precipitated soy protein isolate | MEAD JOHNSON & COMPANY (US) | 1978-02-07 | — | — | US | disclosed |
| US-4042676-A | STANNOUS OXALATE, SODIUM PHYTATE | UNION CARBIDE CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363502-A1 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration | IGFBP6, SIRT6, STRA6 | ITPR3 36/4885ITPR2 66/4885ITPR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.